{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T12:56:22Z","timestamp":1774097782676,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kafr El Shiekh University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although migraine is the second most prevalent form of headache, its preventive treatment has some contraindications and complications. It has been postulated that lacosamide might inhibit CGRP release in the trigeminal system, which could contribute to migraine management. We aimed to evaluate the efficacy and safety of lacosamide as an alternative medication to propranolol for preventing episodic migraine, especially in patients who cannot tolerate propranolol and approved antiseizure medicines for migraine prevention. We recruited patients with episodic migraines; we had two groups: lacosamide group who received lacosamide 50\u00a0mg once daily for 1 week, then twice daily from the 8th day till the 90th day; propranolol group who received propranolol 40\u00a0mg twice daily for 1 week, then 80\u00a0mg twice daily from the 8th till the 90th day. 574 completed the study. In episodic migraine patients, there was no significant difference in the MMD in the last 4 weeks of treatment compared to baseline, the percentage of patients who achieved &gt; 50% reduction in migraine days, reduction in MMD that required acute medication in the last 4 weeks, reduction in HIT score compared to baseline in both groups with\n                    <jats:italic>P<\/jats:italic>\n                    -values 0.13, 0.22, 0.57, and 0.61 respectively. In episodic migraine patients, the regular use of lacosamide 50 mg Bid for 3 months yielded reductions in the monthly migraine days, migraine days that required acute medications, and HIT6 score comparable to those achieved using propranolol 80mg Bid. Lacosamide was well-tolerated by migraine patients. Trial registration: registered on clinicaltrial.gov, NCT05851781\u201430\/04\/2023.\n                  <\/jats:p>","DOI":"10.1007\/s12035-026-05756-5","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T11:58:55Z","timestamp":1774094335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lacosamide Versus Propranolol in Episodic Migraine, a Randomized Controlled Double-blinded Trial"],"prefix":"10.1007","volume":"63","author":[{"given":"Mohamed G.","family":"Zeinhom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheren G.","family":"Rezk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mahmoud","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherihan Rezk","family":"ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"5756_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08373-7","author":"MA Farid","year":"2025","unstructured":"Farid MA, Zeinhom MG, Ahmed SR, Ramadan ES (2025) Factors influencing the occurrence and characteristics of white matter hyperintensities on the brain imaging of migraine patients. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-025-08373-7","journal-title":"Neurol Sci"},{"issue":"4","key":"5756_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S1474-4422(08)70062-0","volume":"7","author":"R Jensen","year":"2008","unstructured":"Jensen R, Stovner LJ (2008) Epidemiology and comorbidity of headache. Lancet Neurol 7(4):354\u2013361. https:\/\/doi.org\/10.1016\/S1474-4422(08)70062-0","journal-title":"Lancet Neurol"},{"issue":"12","key":"5756_CR3","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/j.1468-2982.2009.01874.x","volume":"29","author":"S Cevoli","year":"2009","unstructured":"Cevoli S et al (2009) Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia 29(12):1285\u20131293. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01874.x","journal-title":"Cephalalgia"},{"issue":"9","key":"5756_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735","volume":"44","author":"F Puledda","year":"2024","unstructured":"Puledda F et al (2024) International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia 44(9):03331024241269735. https:\/\/doi.org\/10.1177\/03331024241269735","journal-title":"Cephalalgia"},{"key":"5756_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03302-7","author":"N Siersb\u00e6k","year":"2023","unstructured":"Siersb\u00e6k N, Kilsdal L, Jervelund C, Antic S, Bendtsen L (2023) Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC Neurol. https:\/\/doi.org\/10.1186\/s12883-023-03302-7","journal-title":"BMC Neurol"},{"key":"5756_CR6","doi-asserted-by":"publisher","unstructured":"Krymchantowski AV, Krymchantowski AG, Pimentel ML, da Cunha Jevoux C, Cotrik EM (2025) A systematic review and meta-analysis of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) and gepants for episodic or chronic migraine with or without medication overuse\u00a0headache. SN Compr Clin Med. https:\/\/doi.org\/10.1007\/s42399-025-02059-z","DOI":"10.1007\/s42399-025-02059-z"},{"issue":"7","key":"5756_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130733","volume":"10","author":"JL Jackson","year":"2015","unstructured":"Jackson JL et al (2015) A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One 10(7):e0130733. https:\/\/doi.org\/10.1371\/journal.pone.0130733","journal-title":"PLoS One"},{"key":"5756_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.694381","volume":"12","author":"C Yang","year":"2021","unstructured":"Yang C, Peng Y, Zhang L, Zhao L (2021) Safety and tolerability of lacosamide in patients with epilepsy: a systematic review and meta-analysis. Front Pharmacol 12:12. https:\/\/doi.org\/10.3389\/fphar.2021.694381","journal-title":"Front Pharmacol"},{"issue":"14","key":"5756_CR9","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","volume":"81","author":"E Cernuda-Moroll\u00f3n","year":"2013","unstructured":"Cernuda-Moroll\u00f3n E, Larrosa D, Ram\u00f3n C, Vega J, Mart\u00ednez-Camblor P, Pascual J (2013) Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81(14):1191\u20131196.https:\/\/doi.org\/10.1212\/WNL.0b013e3182a6cb72","journal-title":"Neurology"},{"key":"5756_CR10","doi-asserted-by":"publisher","unstructured":"Greco MC, Capuano A, Navarra P, Tringali G (2016) Lacosamide inhibits calcitonin gene-related peptide production and release at trigeminal level in the rat. Eur J Pain 20(6):959\u2013966. https:\/\/doi.org\/10.1002\/ejp.820","DOI":"10.1002\/ejp.820"},{"key":"5756_CR11","doi-asserted-by":"publisher","unstructured":"Elgamal S, Ahmed SR, Nahas MM, Hendawy SR, Elshafei O, Zeinhom MG (2024) The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial. Acta Neurol Belg 124(3):965\u2013 972.\u00a0https:\/\/doi.org\/10.1007\/s13760-024-02499-9","DOI":"10.1007\/s13760-024-02499-9"},{"key":"5756_CR12","doi-asserted-by":"publisher","unstructured":"(2013) \u201cThe International Classification of Headache Disorders, 3rd edition (beta version).,\u201d Cephalalgia 33(9):629\u2013808.\u00a0https:\/\/doi.org\/10.1177\/0333102413485658","DOI":"10.1177\/0333102413485658"},{"key":"5756_CR13","doi-asserted-by":"publisher","unstructured":"13. Olesen J et al (2013) \u201cThe International Classification of Headache Disorders, 3rd edn (beta version),\u201d.\u00a0Cephalalgia 33(9):629\u2013808.\u00a0https:\/\/doi.org\/10.1177\/0333102413485658","DOI":"10.1177\/0333102413485658"},{"key":"5756_CR14","doi-asserted-by":"publisher","unstructured":"Chowdhury D  et al (2022) TOP-PRO study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia 42(4\u20135):396\u2013 408.\u00a0https:\/\/doi.org\/10.1177\/03331024211047454","DOI":"10.1177\/03331024211047454"},{"key":"5756_CR15","doi-asserted-by":"publisher","unstructured":"Meissner K  et al (2013) Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern Med 17(21):1941\u20131951.\u00a0https:\/\/doi.org\/10.1001\/jamainternmed.2013.10391","DOI":"10.1001\/jamainternmed.2013.10391"},{"issue":"1","key":"5756_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01889-x","volume":"25","author":"A Raggi","year":"2024","unstructured":"Raggi A et al (2024) Hallmarks of primary headache: part 1\u2013migraine. J Headache Pain (1):16. https:\/\/doi.org\/10.1186\/s10194-024-01889-x","journal-title":"J Headache Pain"},{"key":"5756_CR17","doi-asserted-by":"publisher","unstructured":"Hus\u00f8y AK, Steiner TJ (2025) GBD 2023: over twice the health loss from headache disorders among females compared with males, and one fifth of the loss is attributable to medication overuse. J Headache Pain.\u00a0https:\/\/doi.org\/10.1186\/s10194-025-02192-z","DOI":"10.1186\/s10194-025-02192-z"},{"key":"5756_CR18","doi-asserted-by":"publisher","unstructured":"Zeinhom MG  et al (2025) Efficacy and tolerability of valproate versus topiramate in migraine prevention, a randomized controlled multi-center trial. J Clin Neurosci. https:\/\/doi.org\/10.1016\/j.jocn.2025.111156","DOI":"10.1016\/j.jocn.2025.111156"},{"key":"5756_CR19","doi-asserted-by":"publisher","unstructured":"Iba C, Unekawa M, Ihara K, Izawa Y, Nakahara J, Takizawa T (2025) Effect of lacosamide on cortical spreading depolarization in mice. J Headache Pain. https:\/\/doi.org\/10.1186\/s10194-025-02099-9","DOI":"10.1186\/s10194-025-02099-9"},{"key":"5756_CR20","doi-asserted-by":"publisher","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology 78(17):1337\u20131345. https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d20","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"5756_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251396529","author":"MG Zeinhom","year":"2025","unstructured":"Zeinhom MG et al (2025) Lacosamide versus topiramate in episodic migraine: a randomized controlled double-blinded trial. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864251396529","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"5756_CR22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB et al (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0","journal-title":"Lancet Neurol"},{"issue":"2","key":"5756_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/01.ajp.0000210957.39621.b2","volume":"23","author":"RL Rauck","year":"2007","unstructured":"Rauck RL, Shaibani A, Biton V, Simpson J, Koch B (2007) Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 23(2):150\u2013158. https:\/\/doi.org\/10.1097\/01.ajp.0000210957.39621.b2","journal-title":"Clin J Pain"},{"issue":"8","key":"5756_CR24","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jpain.2009.01.322","volume":"10","author":"A Shaibani","year":"2009","unstructured":"Shaibani A et al (2009) Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 10(8):818\u2013828. https:\/\/doi.org\/10.1016\/j.jpain.2009.01.322","journal-title":"J Pain"},{"issue":"1","key":"5756_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3695-7","volume":"20","author":"ME Carmland","year":"2019","unstructured":"Carmland ME et al (2019) Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial. Trials 20(1):588. https:\/\/doi.org\/10.1186\/s13063-019-3695-7","journal-title":"Trials"},{"issue":"1","key":"5756_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/ejp.2165","volume":"28","author":"ME Carmland","year":"2024","unstructured":"Carmland ME et al (2024) The effect of lacosamide in peripheral neuropathic pain: a randomized, double-blind, placebo-controlled, phenotype-stratified trial. Eur J Pain 28(1):105\u2013119. https:\/\/doi.org\/10.1002\/ejp.2165","journal-title":"Eur J Pain"},{"key":"5756_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.712717","author":"L Hou","year":"2021","unstructured":"Hou L et al (2021) Clinical efficacy and safety of lacosamide as an adjunctive treatment in adults with refractory epilepsy. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2021.712717","journal-title":"Front Neurol"},{"key":"5756_CR28","doi-asserted-by":"publisher","unstructured":"Shin\u00a0YW  et al (2021) Tolerability of lacosamide rapid dose titration: a randomized, multicenter, prospective, open-label study. Epilepsy Behav 115:107663.\u00a0https:\/\/doi.org\/10.1016\/j.yebeh.2020.107663","DOI":"10.1016\/j.yebeh.2020.107663"},{"key":"5756_CR29","doi-asserted-by":"publisher","unstructured":"Luk ME, Tatum WO, Patel AV, Nau KM, Freeman WD (2012) The safety of lacosamide for treatment of seizures and seizure prophylaxis in adult hospitalized patients. Neurohospitalist 2(3):77\u2013 81.\u00a0https:\/\/doi.org\/10.1177\/1941874412446200","DOI":"10.1177\/1941874412446200"},{"key":"5756_CR30","doi-asserted-by":"publisher","unstructured":"Domingues RB, Silva AL, Domingues SA, Aquino CC, Kuster GW (2009) A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr 67(4): 973\u2013977.\u00a0https:\/\/doi.org\/10.1590\/S0004-282X2009000600002","DOI":"10.1590\/S0004-282X2009000600002"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-05756-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-05756-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-05756-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T11:58:55Z","timestamp":1774094335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-05756-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5756"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-05756-5","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study had the approval of the ethical committee of Kafr El-sheikh University, and the ethical reference number is (KFSIRB200-753). All methods of our trial were performed following the guidelines and regulations of the Faculty of Medicine Kafr El-sheikh University (FMKFS), which is organized and operated according to the guidelines of the International Council on Harmonization ICH), Anesthesiology and the Islamic Organization for Medical Service (IOMS), the United States Office for Human Research Protections, and the United States Code of Federal Regulations, and operates under Federal Wide Assurance no (FWA00001785).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Before randomization, formal written informed consent was obtained from the included patients or their first-degree relatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"512"}}